Liquidia Found to Infringe United Therapeutics Patent in Court Ruling

MT Newswires Live

4 hours ago

Liquidia (LQDA) said a federal court in Delaware ruled that that the company infringed two claims of a United Therapeutics (UTHR) patent covering the use of inhaled treprostinil to treat pulmonary hypertension associated with interstitial lung disease, including dry-powder formulations.

Liquidia shares tumbled 48% in Wednesday trading, while United Therapeutics rose 12%.

The case centers on Liquidia's Yutrepia inhalation powder. The court found two claims of US Patent 11,826,327 valid and infringed, while the remaining asserted claims were ruled invalid, Liquidia said Wednesday in a statement.

The parties must submit a proposed form of judgment within one week. United Therapeutics has asked the court for injunctive relief that would restrict Yutrepia's market availability, according to the statement.

Liquidia said it cannot estimate potential outcomes or financial exposure at this stage.

United Therapeutics didn't immediately reply to a request for comment from MT Newswires.

Price: 36.85, Change: -33.84, Percent Change: -47.87

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/news/2672109781"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2672109781\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2672109781?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-01 02:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2672109781","market":"us","top_or_hot":-1,"title":"Liquidia Found to Infringe United Therapeutics Patent in Court Ruling","media":"MT Newswires Live","content":"<html><body><p> Liquidia (LQDA) said a federal court in <a href=\"https://laohu8.com/S/VMM\">Delaware</a> ruled that that the company infringed two claims of a United <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (UTHR) patent covering the use of inhaled treprostinil to treat pulmonary hypertension associated with interstitial lung disease, including dry-powder formulations.</p><p>Liquidia shares tumbled 48% in Wednesday trading, while United Therapeutics rose 12%.</p><p>The case centers on Liquidia's Yutrepia inhalation powder. The court found two claims of US Patent 11,826,327 valid and infringed, while the remaining asserted claims were ruled invalid, Liquidia said Wednesday in a statement.</p><p>The parties must submit a proposed form of judgment within one week. United Therapeutics has asked the court for injunctive relief that would restrict Yutrepia's market availability, according to the statement.</p><p>Liquidia said it cannot estimate potential outcomes or financial exposure at this stage.</p><p>United Therapeutics didn't immediately reply to a request for comment from MT Newswires.</p><p>Price: 36.85, Change: -33.84, Percent Change: -47.87</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Liquidia Found to Infringe United Therapeutics Patent in Court Ruling</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLiquidia Found to Infringe United Therapeutics Patent in Court Ruling\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-10-01 02:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Liquidia (LQDA) said a federal court in <a href=\"https://laohu8.com/S/VMM\">Delaware</a> ruled that that the company infringed two claims of a United <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (UTHR) patent covering the use of inhaled treprostinil to treat pulmonary hypertension associated with interstitial lung disease, including dry-powder formulations.</p><p>Liquidia shares tumbled 48% in Wednesday trading, while United Therapeutics rose 12%.</p><p>The case centers on Liquidia's Yutrepia inhalation powder. The court found two claims of US Patent 11,826,327 valid and infringed, while the remaining asserted claims were ruled invalid, Liquidia said Wednesday in a statement.</p><p>The parties must submit a proposed form of judgment within one week. United Therapeutics has asked the court for injunctive relief that would restrict Yutrepia's market availability, according to the statement.</p><p>Liquidia said it cannot estimate potential outcomes or financial exposure at this stage.</p><p>United Therapeutics didn't immediately reply to a request for comment from MT Newswires.</p><p>Price: 36.85, Change: -33.84, Percent Change: -47.87</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"UTHR","symbol_name":"美国联合医疗","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2672109781","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2672109781","pubTimestamp":1790792859,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Liquidia (LQDA) said a federal court in Delaware ruled that that the company infringed two claims of a United Therapeutics (UTHR) patent covering the use of inhaled treprostinil to treat pulmonary hyp","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"UTHR":"美国联合医疗","BK4007":"制药","LQDA":"Liquidia Technologies Inc","BK4139":"生物科技","LU1699723380.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","BK4532":"文艺复兴科技持仓","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC"},"translate_title":"法院裁决认定 Liquidia 侵犯 United Therapeutics 专利","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LQDA":1,"UTHR":1.5},"content_text":"Liquidia (LQDA) said a federal court in Delaware ruled that that the company infringed two claims of a United Therapeutics (UTHR) patent covering the use of inhaled treprostinil to treat pulmonary hypertension associated with interstitial lung disease, including dry-powder formulations.Liquidia shares tumbled 48% in Wednesday trading, while United Therapeutics rose 12%.The case centers on Liquidia's Yutrepia inhalation powder. The court found two claims of US Patent 11,826,327 valid and infringed, while the remaining asserted claims were ruled invalid, Liquidia said Wednesday in a statement.The parties must submit a proposed form of judgment within one week. United Therapeutics has asked the court for injunctive relief that would restrict Yutrepia's market availability, according to the statement.Liquidia said it cannot estimate potential outcomes or financial exposure at this stage.United Therapeutics didn't immediately reply to a request for comment from MT Newswires.Price: 36.85, Change: -33.84, Percent Change: -47.87","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}